Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 2/20 | 0.46 |
| ▸ | TNKS | O95271 | 3/20 | 0.42 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10322494 | 0.87 | KMT2A (0.47) | HTR3ATNKSPARP1HRH4KDM4E | |
| SCHEMBL10324192 | 0.78 | TNKS (0.43) | HTR3ATNKSHRH4KDM4EALDH1A1 | |
| SCHEMBL10322786 | 0.77 | KDM4E (0.45) | HTR3ATNKSPARP1HRH4KDM4E | |
| SCHEMBL10322342 | 0.76 | POLB (0.47) | ALDH1A1POLBRAB9AL3MBTL1 | |
| SCHEMBL10322440 | 0.75 | DYRK1A (0.61) | KDM4EALDH1A1RAB9AL3MBTL1KMT2A | |
| SCHEMBL10322753 | 0.75 | DYRK1A (0.61) | ALDH1A1 | |
| SCHEMBL31500280 | 0.73 | HTR3A (0.48) | HTR3AHRH4KDM4EALDH1A1RAB9A | |
| SCHEMBL4763427 | 0.72 | MAPT (0.53) | HTR3AHRH4ALDH1A1POLBL3MBTL1 | |
| SCHEMBL14558281 | 0.72 | WNT1 (0.49) | HTR3AHRH4KDM4EALDH1A1RAB9A | |
| SCHEMBL10322179 | 0.71 | KDM4E (0.55) | KDM4EALDH1A1POLBGAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012098066-A1 | 1,6- AND 1,8-NAPHTHYRIDINES USEFUL AS DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| US-20120184562-A1 | 1,6- AND 1,8-NAPHTHYRIDINES | LUK KIN-CHUN (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184562-A1 | 1,6- AND 1,8-NAPHTHYRIDINES | LUK KIN-CHUN (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184562-A1 | 1,6- AND 1,8-NAPHTHYRIDINES | LUK KIN-CHUN (US) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184562-A1 | 1,6- AND 1,8-NAPHTHYRIDINES | PSEN1, BRCA1, PSEN2 | HTR3A 753/4885TNKS 465/4885PARP1 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.